Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

975
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
975
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026
Same author

Reaching for the cure as progeria research comes of age at the 12th international scientific workshop.

Nature aging·2026
Same author

Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Predictors of mortality of pediatric cancer patients admitted to the intensive care unit in a low-middle-income country.

Frontiers in pediatrics·2026
Same author

Descriptive and molecular analysis of pineal parenchymal tumors with clinical correlation.

BMC cancer·2025
Same author

Lonafarnib clinical trials demonstrate uncoupling of the muscle-bone unit in Hutchinson-Gilford Progeria Syndrome.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025

Video Experimental Relacionado

Updated: Feb 11, 2026

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

4.1K

La relación entre el tratamiento con Lonafarnib y la ausencia de tratamiento con la tasa de mortalidad en pacientes

Leslie B Gordon1,2,3, Heather Shappell4, Joe Massaro4

  • 1Department of Pediatrics, Division of Genetics, Hasbro Children's Hospital, Providence, Rhode Island.

JAMA
|May 1, 2018
PubMed
Resumen
Este resumen es generado por máquina.

La monoterapia con Lonafarnib redujo significativamente la mortalidad en niños con síndrome de Hutchinson-Gilford progeria (HGPS), una rara enfermedad de envejecimiento prematuro. Este estudio sugiere el lonafarnib como un tratamiento potencial para el HGPS, mejorando las tasas de supervivencia.

Más Videos Relacionados

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
03:40

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome

Published on: April 25, 2025

1.2K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.9K

Videos de Experimentos Relacionados

Last Updated: Feb 11, 2026

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome
06:57

Transaxillary First Rib Resection for Treatment of the Thoracic Outlet Syndrome

Published on: September 13, 2020

4.1K
Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome
03:40

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome

Published on: April 25, 2025

1.2K
Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Author Spotlight: Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

1.9K

Área de la Ciencia:

  • Genética y Biología Molecular
  • Medicina pediátrica
  • Farmacología

Sus antecedentes:

  • El síndrome de Hutchinson-Gilford progeria (HGPS) es un trastorno genético raro y fatal caracterizado por un envejecimiento prematuro rápido.
  • Actualmente, no existen tratamientos aprobados para el HGPS, lo que pone de relieve la necesidad urgente de intervenciones terapéuticas.

Objetivo del estudio:

  • Investigar la asociación entre la monoterapia con lonafarnib y las tasas de mortalidad en niños diagnosticados con HGPS.
  • Evaluar la eficacia del lonafarnib, un inhibidor de la proteína farnesiltransferasa, como tratamiento potencial para el SGH.

Principales métodos:

  • Se utilizó un diseño de estudio de cohorte, comparando a pacientes tratados de dos ensayos clínicos con una cohorte de pacientes no tratados de un estudio de historia natural.
  • Para analizar las tasas de mortalidad se utilizó la regresión condicional de riesgos proporcionales de Cox, ajustando por edad, sexo y continente de residencia.
  • Se recopilaron datos de seguimiento de pacientes hasta el 1 de enero de 2018.

Principales resultados:

  • El tratamiento con Lonafarnib se asoció con una tasa de mortalidad significativamente menor tanto en el análisis primario como en el secundario.
  • En el análisis primario, la tasa de mortalidad fue del 3,7% en pacientes tratados frente al 33,3% en pacientes no tratados (razón de riesgo, 0,12; P=0,04).
  • En el análisis de cohorte combinado, la mortalidad fue del 6,3% en pacientes tratados frente al 27,0% en pacientes no tratados (razón de riesgo, 0,23; P=,04).

Conclusiones:

  • La monoterapia con Lonafarnib demostró una asociación significativa con la reducción de la mortalidad en pacientes con HGPS durante una mediana de seguimiento de 2,2 años.
  • Estos hallazgos sugieren que el lonafarnib puede ser una opción terapéutica prometedora para los niños con HGPS.
  • La naturaleza observacional del estudio requiere una interpretación cautelosa, pero los resultados justifican una mayor investigación.